Long-Term Prognosis of Hyperferritinemia Induced by Intravenous Iron Therapy in Patients Undergoing Maintenance Hemodialysis: A 10-Year, Single-Center Study
Table 2
Comparison of patients with initial ferritin levels >500 ng/mL categorized by ferritin levels at the end of the 10-year follow-up period.
n
<300 ng/mL
n
≥300 ng/mL
value
Sex
21
4
0.6a
Male
11
(52%)
1
(25%)
Female
10
(48%)
3
(75%)
Primary disease
21
4
0.8a
ADPKD
0
(0%)
0
(0%)
AKI
0
(0%)
0
(0%)
DM
8
(38%)
1
(25%)
Glomerulonephritis
9
(43%)
3
(75%)
IgA nephropathy
3
(14%)
0
(0%)
Renal tuberculosis
1
(5%)
0
(0%)
Nephrosclerosis
0
(0%)
0
(0%)
Mortality (1000 person-year)
21
71
4
205
–
Incidence of infection (1000 person-year)
21
37
4
110
–
Incidence of CCVD (1000 person-year)
21
89
4
134
–
Incidence of malignancy (1000 person-year)
21
65
4
0
–
Age
21
63
(54, 73)
4
60
(48, 72)
0.5b
Dialysis vintage
21
6
(3, 18)
4
8
(3, 22)
0.9b
Initial ferritin (ng/ml)
21
797
(591, 1210)∗
4
1240
(1068, 1893)∗
0.05b
Months to decrease below 300 ng/ml
21
24
(11, 47)∗
4
–
–b
ADPKD, autosomal dominant polycystic kidney disease; AKI, acute kidney injury; DM, diabetes mellitus; CCVD, cerebrovascular and cardiovascular diseases. Data are presented as n (%), mean ± standard deviation, and median (interquartile range). values: a, Fisher’s exact test; b, the Mann–Whitney U test. .
